8-K: Citius Pharma Prepares LYMPHIR Launch, Reports Positive Mino-Lok Data

Citius Pharmaceuticals, Inc. announces FDA approval and Q4 2025 commercialization plans for LYMPHIR, alongside positive Phase 3 results for Mino-Lok.

Summary

• LYMPHIR (denileukin diftitox-cxdl) received FDA approval in August 2024 for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
• Commercialization of LYMPHIR is planned for Q4 2025, targeting an estimated $400M+ addressable U.S. market with growth opportunities.
• Citius Oncology, Inc. (NASDAQ: CTOR), a majority-owned (~79%) subsidiary of Citius Pharmaceuticals, Inc., was spun off in August 2024 to focus on LYMPHIR.
• Citius Pharmaceuticals intends to distribute a portion of its CTOR shares to CTXR shareholders in the future.
• The company has invested over $90 million in LYMPHIR to date, covering upfront purchase, development, pre-commercial efforts, and spinout costs.
• Mino-Lok, a novel antibiotic lock solution for catheter-related bloodstream infections (CLABSI), completed its Phase 3 trial in 2024 with positive topline data, meeting primary and secondary endpoints.
• The estimated global market for Mino-Lok is expected to exceed $2 billion.
• Halo-Lido, a prescription therapy under development for hemorrhoids, completed its Phase 2b trial with positive results, showing a meaningful reduction in symptom severity.

Sentiment

Score: 9

Explanation: The filing presents highly positive news with FDA approval for LYMPHIR, successful Phase 3 trial results for Mino-Lok, and positive Phase 2b data for Halo-Lido. The company is actively preparing for commercialization and exploring growth opportunities, indicating strong progress across its pipeline.

Positives

• FDA approval of LYMPHIR in August 2024 for CTCL, marking the first new systemic CTCL therapy since 2018.
• LYMPHIR benefits from 12-year BLA exclusivity and targets an estimated $400M+ addressable U.S. market with significant growth opportunities.
• Extensive pre-commercial activities for LYMPHIR are nearing completion, including manufactured inventory, supply chain agreements, securing a new permanent J-code, NCCN guideline inclusion, and hiring key sales force management.
• Positive topline data from the Mino-Lok Phase 3 trial, which met primary and secondary endpoints, demonstrating superiority in extending time to catheter failure (p-value = 0.0006) and achieving overall treatment success (p-value = 0.0025).
• Mino-Lok was well-tolerated with no drug-related serious adverse events, and its global market potential is estimated to exceed $2 billion.
• Positive Phase 2b results for Halo-Lido, showing meaningful reduction in hemorrhoidal symptom severity and validating the Patient Reported Outcome (PRO) instrument for a pivotal Phase 3 study.
• The company maintains a diversified late-stage biopharmaceutical pipeline with commercialization anticipated in 2025.
• Strong management and shareholder alignment, evidenced by $26.5 million invested by founders.

Risks

• The accuracy of forward-looking statements is dependent upon future events and involves known and unknown risks, uncertainties, and other factors beyond the company's control that may cause actual results to differ materially.
• There is inherent uncertainty in the underlying assumptions and estimates used for expected sales or profitability projections.
• The company does not make public projections regarding expected sales or profitability due to inherent uncertainties.
• The intended distribution timing of CTOR shares to CTXR shareholders is subject to performance, market conditions, and other factors, including applicable restrictions on transfer.

Future Outlook

Citius Pharmaceuticals plans the commercial launch of LYMPHIR in Q4 2025, targeting a significant U.S. market. The company anticipates further evaluation of LYMPHIR in combination with PD-1 inhibitors and CAR T therapies, with preliminary data expected in Q4 2025/Q1 2026 and Q1 2026, respectively. Citius also intends to monetize Halo-Lido with a strategic or financial partner and is in active discussions for ex-U.S. distribution partners for LYMPHIR.

Management Comments

• Citius has invested >$90 million in LYMPHIR to date.
• Commercial launch readiness nearing completion through disciplined financial strategy.
• Citius's commitment to access [for LYMPHIR].
• Citius anticipates monetizing the value of this asset [Halo-Lido] with a strategic or financial partner.

Industry Context

LYMPHIR enters the CTCL market as the first new systemic therapy since 2018, offering a differentiated mechanism of action (targeting the IL-2 receptor) in a non-curative treatment landscape where patients often cycle through multiple therapies. Mino-Lok addresses a significant unmet need in catheter-related bloodstream infections, as no currently approved drugs salvage infected catheters, potentially changing the standard of care by offering a non-invasive, cost-effective alternative to catheter removal. Halo-Lido aims to be the first FDA-approved prescription product for hemorrhoids, a condition affecting millions.

Comparison to Industry Standards

• LYMPHIR is positioned as the 'first new systemic CTCL therapy since 2018,' highlighting its novelty compared to existing treatments.
• LYMPHIR's differentiated MOA targeting the IL-2 receptor is presented as an advantage over current therapies which may require CD30+ biomarker (e.g., Adcetris), cause peripheral neuropathy, or have cumulative bone marrow toxicity.
• Mino-Lok is described as the 'only treatment designed to salvage infected catheters causing CLABSI' and 'No drugs currently approved to salvage catheters in patients with central-line associated bloodstream infections (CLABSI) or catheter-related bloodstream infections (CRBSI),' indicating a significant unmet need and potential to set a new standard of care.
• Halo-Lido is positioned as 'Potentially the first FDA-approved prescription product to treat hemorrhoids,' suggesting it could fill a gap in the market for a regulated, effective treatment.

Stakeholder Impact

• Shareholders (CTXR): Potential for increased value through LYMPHIR commercialization, positive pipeline developments, and future distribution of CTOR shares.
• Shareholders (CTOR): Direct investment in a company with an FDA-approved oncology product nearing commercial launch.
• Patients (CTCL): Access to a new systemic therapy (LYMPHIR) for relapsed or refractory CTCL, the first since 2018.
• Patients (CLABSI/CRBSI): Potential for a novel treatment (Mino-Lok) to salvage infected catheters, reducing discomfort and complications.
• Healthcare Providers: New treatment options (LYMPHIR, Mino-Lok) and a potential prescription therapy for hemorrhoids (Halo-Lido) to improve patient care.

Next Steps

• Commercialization of LYMPHIR in Q4 2025.
• Hire and onboard salesforce to initiate LYMPHIR sales.
• Ship LYMPHIR product to wholesalers.
• Implement digital media plan and ad campaign for LYMPHIR.
• Launch Patient Services Hub for LYMPHIR.
• Expand Named Patient Program for LYMPHIR to ex-U.S. markets.
• Further evaluation of LYMPHIR in combination with KEYTRUDA for recurrent or metastatic solid tumors (Phase 1 preliminary data anticipated Q4 2025/Q1 2026).
• Further evaluation of LYMPHIR in combination with CAR T therapies for high-risk relapsed/refractory B-cell lymphomas (Phase 1 preliminary results anticipated Q1 2026).
• Ongoing FDA engagement regarding next steps for Halo-Lido.
• Monetizing Halo-Lido with a strategic or financial partner.
• Active discussions with additional prospective distribution partners for LYMPHIR across several European Union member states, South America, and select Middle Eastern territories.
• Distribution of a portion of CTOR shares to CTXR shareholders in the future.

Key Dates

Recommendation

The company has achieved significant milestones with the FDA approval of LYMPHIR, a first-in-class systemic therapy for CTCL, and positive Phase 3 data for Mino-Lok, addressing a critical unmet need in catheter infections. With LYMPHIR's commercial launch imminent in Q4 2025 and a substantial addressable market, coupled with a strong pipeline and clear monetization strategy for Halo-Lido, the company is well-positioned for substantial growth. The spin-off of Citius Oncology and the planned distribution of shares to CTXR shareholders further enhance shareholder value. These developments indicate a strong positive trajectory and significant upside potential.

Keywords

Citius Pharmaceuticals, CTXR, LYMPHIR, CTCL, Cutaneous T-cell Lymphoma, FDA Approval, Mino-Lok, CLABSI, Catheter-Related Bloodstream Infection, Halo-Lido, Hemorrhoids, Biopharmaceutical, Oncology, Infectious Disease, Dermatology, Drug Development, Phase 3 Trial, Commercialization